A study comparing paroxetine placebo and imipramine in depressed patients

Effects of acute and chronic antidepressant treatments on memory performance: a comparison between paroxetine and imipramine

“…In addition, imipramine and paroxetine possess anticholinergic properties that may be responsible for memory impairments. Among selective SSRIs, paroxetine shows a relatively high affinity for muscarinic receptors and is not devoid of anticholinergic side effects (Fujishiro et al 2002), but paroxetine anticholinergic side effects are reduced in comparison to those induced by imipramine (Feighner et al 1993;Arminen et al 1994). The extended harmful effect that we observed in those tasks after chronic treatment with imipramine, but not with paroxetine, could be partially attributable to this discrepancy.…”

“…Paroxetine induces side effects like anticholinergic and cardiovascular adverse effects but less than those of TCAs (Feighner et al 1993;Arminen et al 1994). The aim of our study was to compare in rats the effects of acute and chronic treatments with paroxetine and imipramine, a reference TCA with non-selective 5-HT and NE inhibitor properties, on learning and memory performances that require the contribution of PFC networks.…”

Paroxetine in the Elderly: A Comparative Meta-Analysis against Standard Antidepressant Pharmacotherapy

“…Studies in young adults have shown paroxetine to be equally efficacious as the tricyclic antidepressants (TCA) [2,3]. The antidepressant activity is robust, paroxetine being effective in treating most types of depression, including severe (melancholic) depression [4] and depression associated with anxiety/agitation [5], Paroxe-tine had a beneficial effect on suicidal thoughts and reduced the emergence of suicidality [6], As well as being effective in short term treatment, paroxetine has proven effica cy in preventing both the relapse and recur rence of depressive illness [7], Compared with the TCAs, paroxetine was found to have im proved safety and tolerability.…”

Selective Serotonin Reuptake Inhibitors

“…One caveat concerning these studies is that some included only active controls and simply found no difference between, for example, an SSRI and a TCA, which does not prove that the SSRI is as efficacious as the TCA but may only reflect the fact that the sample was too small to separate the treatments (Janicak et al 2001). Five double-blind studies have compared various SSRIs with different TCAs in patients with HAM-D scores of 25 or higher (Reimherr et al 1988;Bowden et al 1993;Feighner et al 1993;Pande and Sayler 1993;Kasper et al 1995), three of which included both inpatients and outpatients (Bowden et al 1993;Pande and Sayler 1993;Kasper et al 1995) and two of which were outpatient studies (Reimherr et al 1988;Feighner et al 1993). In the three studies that were placebo-controlled (Reimherr et al 1988;Feighner et al 1993;Kasper et al 1995), the SSRI tested (fluvoxamine, paroxetine, or sertraline) was either found to be superior to both the TCA and placebo or comparable to the TCA and superior to placebo.…”